The effects of nafamostat mesilate (FUT-175) on caerulein-induced acute pancreatitis in the rat
- 34 Downloads
We examined the ability of a highly potent synthetic protease inhibitor, nafamostat mesilate (FUT-175), to protect the rat pancreas against AP induced by a supramaximal dose of caerulein (CR). Rats received a 6-h, continuous intravenous (iv) infusion of either CR alone or CR + a 6-h infusion of either 2.5, 5.0, 10.0, 25.0, or 50.0 mg of FUT-175/kg/h. Pancreas weights and serum chymotrypsinogen concentrations were significantly elevated by approximately 85 and 75%, respectively, over values in saline infused rats. Pancreas weights in rats treated with CR+ FUT-175 at doses from 2.5–25.0 mg/kg/h were significantly reduced by approximately 20% compared to rats given CR along, and histology showed a reduction in the extent and size of acinar cell vacuolization and reduced interstitial edema compared to rats treated with CR alone. Serum chymotrypsinogen concentrations in rats treated with CR and either 5.0 or 10.0 mg of FUT-175/kg/h were significantly lower than in rats given CR alone. Significant mortality occurred in rats infused with FUT-175 at doses of either 25.0 or 50.0 mg of FUT-175/kg/h. These data indicate that serine proteases appear to be involved in the pathogenesis of CR induced AP in rats and that FUT-175 administered in low doses (2.5–10.0 mg/kg/h) provides significant protection against this form of pancreatitis.
Key WordsAcute pancreatitis caerulein FUT-175 protection
Unable to display preview. Download preview PDF.
- 1.Scheele G. Biochemical concepts and markers in acute pancreatitis. Gyr K, Singer M, Singer M, Sarles H. eds., Pancreatitis: concepts and classification. Elsevier, Amsterdam, 1984: 119–125.Google Scholar
- 2.Adler G, Kern HF, Scheele GA. Experimental models and concepts in acute pancreatitis. Go VLW, Gardner JD, Brooks FP, Lebenthal E, DiMagno EP, Scheele GA. eds., The exocrine pancreas: biology, pathobiology, and diseases. Raven Press, New York, 1986: 407–421.Google Scholar
- 9.Iwaki M, Ozeki M, Sato T, Suzuki K, Motoyoshi A, Suzuki S, Fujita S, Aoyama T. Pharmacological studies of FUT-175, nafamstat mesilate. II. Effects on experimental acute pancreatitis. Folia Pharmacol. Japon. 1984; 84: 363–372.Google Scholar
- 12.Wisner JR Jr., McLaughlin RE, Rich KA, Ozawa S, Renner IG. Effects of L-364,718, a new cholecystokinin receptor antagonist, on camostate-induced growth of the rate pancreas. Gastroenterol. 1988; 94: 109–113.Google Scholar
- 13.Adler HL, Roessler EB. Introduction to probability and statistics. 4th ed., W. H. Freeman, San Francisco, 1968.Google Scholar
- 14.Steele RGD, Torie JH. Principles and procedures of statistics. McGraw-Hill, New York, 1960.Google Scholar
- 16.Aoyama T, Ino Y, Ozeki M, Oda M, Sato T, Koshiyama Y, Suzuki S, Fujita M. Pharmacological studies of FUT-175, nafamstat mesilate. I. Inhibition of protease activity ofin vitro andin vivo experiments. Japan. J. Pharmacol. 1984; 35: 203–227.Google Scholar
- 20.Onstad GR, Bubrick M P. Pathophysiology. Toledo-Pereya LH. ed., The pancreas: principles and medical and surgical practice. Wiley, New York, 1985: 97–116.Google Scholar
- 22.Sato K, Watanabe K, Terasawa K, Yokomoto Y, Nagai N, Otani K. Acute toxicity studies of FUT-175 (Nafamstat mesilate) in mice and rats. Principle and Clinics (Japan.) 1984; 18: 227–234.Google Scholar